Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company announced that three abstracts related to its SENTI-202 trial have been selected for presentation at the AACR Annual Meeting 2025 [1][2] Company Overview - Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - The lead program, SENTI-202, targets CD33 and/or FLT3 in hematologic cancers and has shown promising initial clinical data, including MRD-negative complete remissions in 2 of 3 patients as of September 19, 2024 [3] - The company has demonstrated the potential of its Gene Circuits in T cells and other cell and gene therapy modalities, indicating a broad application beyond oncology [3] Upcoming Presentations - The first abstract focuses on clinical data from the SENTI-202 trial, scheduled for presentation on April 27, 2025 [2] - The second abstract presents correlative data from the same trial, to be showcased on April 29, 2025 [2] - The third abstract discusses the selective targeting of AML while protecting healthy stem cells from off-tumor toxicity, to be presented on April 30, 2025 [2]